TOP TEN perturbations for 1553297_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553297_a_at
Selected probe(set): 1553297_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553297_a_at (1553297_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-3.7480898
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):-3.6497116
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

CML study 1 / B-CLL study 5

Relative Expression (log2-ratio):3.1144447
Number of Samples:75 / 441
Experimental CML study 1
Bone marrow samples of patients with chronic myeloid leukemia (CML).
Control B-CLL study 5
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL).

thermal injury study 1 (0-3d) / normal skin tissue

Relative Expression (log2-ratio):3.025033
Number of Samples:3 / 3
Experimental thermal injury study 1 (0-3d)
Burn wound margin samples of the skin 0-3 days post thermal injury.
Control normal skin tissue
Normal skin tissue sample.

IL-4; GM-CSF study 1 (late) / untreated monocyte sample

Relative Expression (log2-ratio):-2.9312677
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (late)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample

Relative Expression (log2-ratio):-2.9112911
Number of Samples:36 / 74
Experimental precursor-B-ALL study 1 (t(1;19)(q23,q13))
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1).
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

ulcerative colitis study 29 (infliximab; 10mg/kg; responder; 30wk) / ulcerative colitis study 29 (infliximab; 10mg/kg; non-responder; 30wk)

Relative Expression (log2-ratio):-2.8561077
Number of Samples:10 / 3
Experimental ulcerative colitis study 29 (infliximab; 10mg/kg; responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 10 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:
Control ulcerative colitis study 29 (infliximab; 10mg/kg; non-responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are non-responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 10 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:

thermal injury study 1 (>7d) / normal skin tissue

Relative Expression (log2-ratio):2.7345848
Number of Samples:3 / 3
Experimental thermal injury study 1 (>7d)
Burn wound margin samples of the skin >7 days post thermal injury.
Control normal skin tissue
Normal skin tissue sample.

ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk) / ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk)

Relative Expression (log2-ratio):-2.7105846
Number of Samples:6 / 3
Experimental ulcerative colitis study 29 (infliximab; 5mg/kg; responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:
Control ulcerative colitis study 29 (infliximab; 5mg/kg; non-responder; 30wk)
Colonic mucosal biopsies from ulcerative colitis patients who are non-responders to infliximab treatment at timepoint 30 weeks (during maintenance phase). At baseline patients had a diagnosis of moderately to severe active ulcerative colitis (Mayo score of 6 to 12). Biopsies were taken 30 weeks after patients received intravenous infusions of 5 mg infliximab per kg body weight. During induction phase (week 0-8) patients received infusions at weeks 0, 2, and 6 and during maintenance phase (weeks 8-46) patients received infusions every 8 weeks beginning at week 14. Clinical response was defined as a decrease from baseline in the total Mayo score of at least three points and at least at 30%, with an accompanying decrease in the subscore for rectal bleeding of at least one point or an absolute subscore for rectal bleeding of 0 or 1. Biopsies were collected from lesions 15 to 20 cm from the anal verge. ATC code:

kidney transplantation study 14 (12 week) / normal B-cell (CD19+) sample

Relative Expression (log2-ratio):2.6831102
Number of Samples:3 / 5
Experimental kidney transplantation study 14 (12 week)
CD19+ B-cell samples derived from kidney transplant patients 12 weeks post-transplantation. Samples were collected 12 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal B-cell (CD19+) sample
CD19+ B-cell samples derived from healthy control subjects.